In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
The league pulled marijuana off its banned list in the new players’ agreement. In the…
In New South Wales, Australia, patients can legally use medical cannabis with a prescription. So…
The clinical evidence is real. The valuations are not. Compass Pathways: $560 million market cap,…
Reading through hundreds of grower responses, one theme emerges above the specific challenges: growing cannabis…
The Tri-State brand built its reputation one pre-roll at a time. Now, after multiple Cannabis…
The Mobb Deep co-founder and Queensbridge native opens The Bridge in Astoria this weekend, with…